Tirzepatide treatment for more than 1 year achieved a median weight reduction of 22.6% compared to 8.1% with short-term treatment in adults with obesity.
Cohort (n=100)
No
Does long-term tirzepatide treatment improve weight loss and cardio-metabolic-kidney outcomes compared to short-term treatment in adults with obesity without T2DM?
Real-world evidence shows that tirzepatide treatment persisting beyond one year provides substantially greater weight loss and cardio-metabolic-kidney benefits compared to shorter-term treatment in adults with obesity.
Absolute Event Rate: -22.6% vs -8.1%
p-value: p=<0.001
Tirzepatide showed greater cumulative benefits across CKM syndrome outcomes during the second treatment year, highlighting the need to overcome adherence barriers in real-world settings.
Rangraze et al. (Fri,) conducted a cohort in Obesity without type 2 diabetes mellitus (n=100). Tirzepatide vs. Short-term treatment (≤ 1 year) was evaluated on Percentage change in body weight (p=<0.001). Tirzepatide treatment for more than 1 year achieved a median weight reduction of 22.6% compared to 8.1% with short-term treatment in adults with obesity.